The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. The growth in this market can be attributed to factors such as the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination.
Prominent players in this market include Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US). These players have adopted various strategies, such as partnerships, agreements, collaborations, expansions, acquisitions, and product/ service launches to further expand their presence in the global bioburden testing market.
To know about the assumptions considered for the study download the pdf brochure
Charles River is the leading player in the bioburden testing market. The company offers traditional as well as innovative technology platforms that help streamline bioburden testing. The company’s wide geographic presence also plays an important role in securing its dominant position in the bioburden testing market. The company focuses on inorganic growth strategies such as acquisitions to further strengthen its position in the market. For instance, in April 2018, Charles River acquired MPI Research (US), a premier nonclinical CRO, to increase its customer base.
Merck KGaA is the second-largest player in the bioburden testing market. The leading position of the company is attributed to its brand recognition and vast product and service portfolio. Merck primarily focuses on the organic growth strategy of expansion to enhance and maintain its share in the market. In the past three years, the company has undertaken as many as six relevant expansion projects in various geographies. For example, in 2018, the company opened the M Lab Collaboration Center in Brazil. In the same year, the company announced its plans to expand its distribution center for life science products in Gillingham, UK.
SGS SA has a strong network of over 2,400 offices and laboratories around the world, SGS is a prominent player in the bioburden testing market. The company has a strong presence in North America, Europe, the Middle East and Africa, Australia, and Asia. Its wide geographical presence provides it a competitive advantage in the market. SGS is also known for providing quality services, and this brand recognition has helped it to maintain its position in the market.
Bioburden Testing Market by Product (Consumables, Instrument (PCR, Microscope)), Test (Anerobic, Mold/Fungi, Aerobic, Spore), Application (Raw Material, Medical Devices, Sterility Testing), End User (Pharma, Biotechnology, CMO) - Global Forecast to 2023
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE